Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.
Biomark Med
; 11(9): 721-731, 2017 09.
Article
en En
| MEDLINE
| ID: mdl-28658966
ABSTRACT
AIM:
Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. MATERIALS &METHODS:
We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups.RESULTS:
A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR] 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR 0.926; p = 0.876) in the latter.CONCLUSION:
This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Actinina
/
Biomarcadores de Tumor
/
Quimioterapia Adyuvante
/
Adenocarcinoma del Pulmón
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Biomark Med
Asunto de la revista:
BIOQUIMICA
/
MEDICINA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Japón